164 related articles for article (PubMed ID: 19593232)
1. Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy.
Koomen ER; Joosse A; Herings RM; Casparie MK; Guchelaar HJ; Nijsten T
Melanoma Res; 2009 Oct; 19(5):327-32. PubMed ID: 19593232
[TBL] [Abstract][Full Text] [Related]
2. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study.
Koomen ER; Joosse A; Herings RM; Casparie MK; Guchelaar HJ; Nijsten T
Ann Oncol; 2009 Feb; 20(2):358-64. PubMed ID: 18725391
[TBL] [Abstract][Full Text] [Related]
3. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?
Koomen ER; Joosse A; Herings RM; Casparie MK; Bergman W; Nijsten T; Guchelaar HJ
Eur J Cancer; 2007 Nov; 43(17):2580-9. PubMed ID: 17950596
[TBL] [Abstract][Full Text] [Related]
4. Estrogens and the risk of complex regional pain syndrome (CRPS).
de Mos M; Huygen FJ; Stricker BH; Dieleman JP; Sturkenboom MC
Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):44-52. PubMed ID: 19111016
[TBL] [Abstract][Full Text] [Related]
5. Incidence of benign and malignant breast disorders in women taking hormones (contraceptive pill or hormonal replacement therapy).
Tzingounis V; Cardamakis E; Ginopoulos P; Argiropoulos G
Anticancer Res; 1996; 16(6C):3997-4000. PubMed ID: 9042326
[TBL] [Abstract][Full Text] [Related]
6. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
7. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study.
Doran MF; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2004 Feb; 31(2):207-13. PubMed ID: 14760786
[TBL] [Abstract][Full Text] [Related]
8. Invasive cutaneous melanoma in The Netherlands, 1989-1990.
Tersmette AC; Coebergh JW; Casparie-van Velsen IJ; Ruiter DJ; van der Rhee HJ; Welvaart K
Eur J Cancer Prev; 1996 Feb; 5(1):69-74. PubMed ID: 8664813
[TBL] [Abstract][Full Text] [Related]
9. A ten-year analysis of demographic trends for cutaneous melanoma: analysis of 2501 cases treated at the University Department of Dermatology in Vienna (1990-1999).
Kittler H; Binder M; Wolff K; Pehamberger H
Wien Klin Wochenschr; 2001 Apr; 113(9):321-7. PubMed ID: 11388077
[TBL] [Abstract][Full Text] [Related]
10. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
[TBL] [Abstract][Full Text] [Related]
11. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
[TBL] [Abstract][Full Text] [Related]
12. Melanoma onset after estrogen, thyroid, and growth hormone replacement therapy.
Caldarola G; Battista C; Pellicano R
Clin Ther; 2010 Jan; 32(1):57-9. PubMed ID: 20171412
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node biopsy in elderly irish patients with malignant melanoma.
Moran DE; Smith MJ; O'Sullivan MJ; Bannon H; Crotty TB; Collins CD; Skehan SJ; O'Higgins N; McDermott EW; Evoy D; Hill AD
Ir Med J; 2007 Apr; 100(4):422-4. PubMed ID: 17566474
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
15. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?
Khoo SK; Chick P
Med J Aust; 1992 Jan; 156(2):124-32. PubMed ID: 1736053
[TBL] [Abstract][Full Text] [Related]
16. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis.
Gandini S; Iodice S; Koomen E; Di Pietro A; Sera F; Caini S
Eur J Cancer; 2011 Nov; 47(17):2607-17. PubMed ID: 21620689
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous melanoma in relation to exogenous hormones and reproductive factors.
Holly EA; Weiss NS; Liff JM
J Natl Cancer Inst; 1983 May; 70(5):827-31. PubMed ID: 6573527
[TBL] [Abstract][Full Text] [Related]
18. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
19. Does hormone replacement therapy and use of oral contraceptives increase the risk of non-melanoma skin cancer?
Birch-Johansen F; Jensen A; Olesen AB; Christensen J; Tjønneland A; Kjær SK
Cancer Causes Control; 2012 Feb; 23(2):379-88. PubMed ID: 22215431
[TBL] [Abstract][Full Text] [Related]
20. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
